ATE180669T1 - Verwendung von pregnanderivaten zur behandlung von tumoren - Google Patents

Verwendung von pregnanderivaten zur behandlung von tumoren

Info

Publication number
ATE180669T1
ATE180669T1 AT94200523T AT94200523T ATE180669T1 AT E180669 T1 ATE180669 T1 AT E180669T1 AT 94200523 T AT94200523 T AT 94200523T AT 94200523 T AT94200523 T AT 94200523T AT E180669 T1 ATE180669 T1 AT E180669T1
Authority
AT
Austria
Prior art keywords
derivatives
pregnander
treat tumors
alpha
tumors
Prior art date
Application number
AT94200523T
Other languages
English (en)
Inventor
Godefridus Hermanus Jo Deckers
Helenius Jan Kloosterboer
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE180669T1 publication Critical patent/ATE180669T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)
AT94200523T 1993-03-05 1994-03-02 Verwendung von pregnanderivaten zur behandlung von tumoren ATE180669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93200631 1993-03-05

Publications (1)

Publication Number Publication Date
ATE180669T1 true ATE180669T1 (de) 1999-06-15

Family

ID=8213673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94200523T ATE180669T1 (de) 1993-03-05 1994-03-02 Verwendung von pregnanderivaten zur behandlung von tumoren

Country Status (14)

Country Link
US (1) US5512556A (de)
EP (1) EP0613687B1 (de)
JP (1) JP3391539B2 (de)
KR (1) KR100312061B1 (de)
AT (1) ATE180669T1 (de)
AU (1) AU671706B2 (de)
CA (1) CA2116829C (de)
DE (1) DE69418744T2 (de)
DK (1) DK0613687T3 (de)
ES (1) ES2134313T3 (de)
GR (1) GR3031114T3 (de)
NO (1) NO307447B1 (de)
NZ (1) NZ260017A (de)
ZA (1) ZA941464B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL181406B1 (pl) * 1994-09-22 2001-07-31 Akzo Nobel Nv Sposób wytwarzania postaci uzytkowych srodka farmaceutycznego zawierajacego co najmniej jeden progestogen i tabletka zawierajaca progestogen PL PL PL PL PL
IL123984A (en) 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
AU763232B2 (en) * 1998-10-16 2003-07-17 Merck Sharp & Dohme B.V. High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one
AU5209600A (en) * 1999-04-06 2000-10-23 Akzo Nobel N.V. Orally active androgens
NZ517281A (en) 1999-09-06 2003-09-26 Akzo Nobel Nv Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11
KR20030029640A (ko) 2000-07-28 2003-04-14 악조 노벨 엔.브이. 16 알파-메틸 또는 에틸 치환 에스트로겐
ES2284946T3 (es) * 2001-10-18 2007-11-16 Norton Healthcare Limited Formulaciones de tibolona.
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
CN1620298A (zh) * 2002-01-22 2005-05-25 阿克佐诺贝尔公司 替勃龙用于治疗与施用阻止内源性雌激素合成的药物有关的疾病
KR20050085024A (ko) * 2002-11-20 2005-08-29 악조 노벨 엔.브이. 티볼론 및 코팅을 포함하는 약학적 정제
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
ZA941464B (en) 1994-09-27
DK0613687T3 (da) 1999-12-06
NZ260017A (en) 1997-06-24
KR940021064A (ko) 1994-10-17
AU671706B2 (en) 1996-09-05
EP0613687A1 (de) 1994-09-07
NO307447B1 (no) 2000-04-10
JP3391539B2 (ja) 2003-03-31
CA2116829C (en) 2004-09-14
AU5754294A (en) 1994-09-08
NO940777D0 (no) 1994-03-04
NO940777L (no) 1994-09-06
DE69418744T2 (de) 1999-11-11
ES2134313T3 (es) 1999-10-01
KR100312061B1 (ko) 2001-12-28
EP0613687B1 (de) 1999-06-02
CA2116829A1 (en) 1994-09-06
JPH072673A (ja) 1995-01-06
GR3031114T3 (en) 1999-12-31
US5512556A (en) 1996-04-30
DE69418744D1 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
ATE193827T1 (de) Verwendung von 1-2-4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
TW229156B (de)
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
TW226375B (de)
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
HU9400908D0 (en) Pharmaceutical compositions for treatng skin disorders
DE69823650D1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
MY130771A (en) 3-azabicyclo [3.1.0] hexane derivatives useful in therapy.
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee